Horizon Therapeutics
1 Horizon Way
Deerfield
IL
60015
United States
650 articles about Horizon Therapeutics
-
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
7/17/2023
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023, prior to the open of the U.S. financial markets.
-
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
7/6/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA® (pegloticase) injection with methotrexate, a commonly used immunomodulator, in ACR Open Rheumatology [https://doi.org/10.1002/acr2.11578].
-
The companies have filed their own suit against the Federal Trade Commission, claiming the FTC’s attempt to legally block their $28 billion merger is unconstitutional.
-
New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
6/30/2023
Horizon Therapeutics plc announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the formation of subclinical transverse myelitis lesions in people with NMOSD.
-
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
6/26/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA for the treatment of active TED.
-
Citing anti-trust issues, six states—California, Illinois, Minnesota, New York, Washington and Wisconsin—are joining the FTC’s legal challenge to Amgen’s nearly $27.8 billion buyout of Horizon.
-
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
6/22/2023
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA ® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED).
-
New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
6/17/2023
Horizon Therapeutics plc announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves’ disease and TED, including among those treated with TEPEZZA.
-
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration
6/17/2023
Horizon Therapeutics plc announced the presentation of new data from the randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA in patients with long disease duration and low Clinical Activity Score, a measure of disease activity.
-
UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
6/12/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis from the N-MOmentum clinical trial of UPLIZNA demonstrating the utility of a robust adjudication process that could improve clinical care decision-making in neuromyelitis optica spectrum disorder (NMOSD) through more accurate and consistent assessment of disease-related attacks.
-
The Federal Trade Commission’s lawsuit takes an unusual strategy, according to legal experts, raising concerns and uncertainties in the biopharma industry.
-
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
6/5/2023
Horizon Therapeutics plc Announces Data from the TEPEZZA ® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting.
-
Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)
6/1/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of new data from the Phase 3 N-MOmentum pivotal trial of UPLIZNA, which offer insights on serum biomarkers that signal acute attacks and disability worsening associated with NMOSD and illustrate the role of UPLIZNA in reducing these biomarker levels, potentially reducing the frequency and severity of these attacks.
-
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
5/31/2023
Horizon Therapeutics plc today announced presentations of new results from the randomized, double-blind, placebo-controlled Phase 2 trial showing dazodalibep, an investigational treatment for Sjögren’s syndrome, may improve some of the most prominent effects of this chronic, systemic autoimmune condition characterized by inflammation of exocrine glands.
-
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
5/31/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new analyses from the MIRROR randomized controlled trial of KRYSTEXXA® (pegloticase) injection with methotrexate show a multi-faceted impact when treating adults living with chronic gout refractory to oral therapy, or uncontrolled gout.
-
Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
5/23/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced plans for the first presentation of data from a Phase 2 study of dazodalibep, the company’s investigational therapy for Sjögren’s syndrome, during the 2023 EULAR European Congress of Rheumatology, May 31 - June 3, 2023, in Milan.
-
The Federal Trade Commission filed a lawsuit Tuesday seeking an injunction to prevent Amgen’s buyout of Horizon Therapeutics, which the agency says would “entrench monopoly drugs.”
-
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
5/16/2023
Horizon Therapeutics plc issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company.
-
Amgen Responds to FTC Action Re: Proposed Acquisition of Horizon Therapeutics
5/16/2023
Amgen issued the following statement in response to the U.S. Federal Trade Commission's complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc:.
-
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
5/9/2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it ranked first in overall corporate reputation among U.S. patient groups who reported working with, or who were familiar with the company.